Beroni Group Announces Appointment of Dr. John Chiplin to Board of Directors

Rhea-AI Summary

Beroni Group (OTCQX: BNIGF) has appointed Dr. John Chiplin as an independent director effective April 1, 2022. Dr. Chiplin brings extensive biotech experience, having previously helmed companies like Polynoma and Benitec Biopharma. His expertise is expected to enhance Beroni's clinical development efforts and support the company’s growth objectives. The appointment comes as Beroni seeks to accelerate its global expansion and raise capital for research and development, particularly in oncology and cell therapies.

Positive

• Appointment of Dr. John Chiplin expected to provide strong leadership and guidance in clinical development.
• Dr. Chiplin's extensive experience in building successful biotech companies may facilitate Beroni's growth.

Negative

• Potential experience gaps in the board could lead to continuity issues.

NEW YORK and SYDNEY, Australia, March 31, 2022 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, announced that it has appointed Dr. John Chiplin as an independent director to Beroni’s Board of Directors effective April 1, 2022. Dr. Chiplin is an accomplished biotech executive and investor with a proven track record of building successful biotech companies.

Dr. John Chiplin, PhD is Managing Director of Newstar Ventures Ltd. and Chairman of the Board of Biotherapy Services, N4 Pharma plc (LSE: N4P) and Scancell Holdings plc. (LSE: SCLP). Dr. Chiplin has significant operational, investment and international experience in the life science and technology industries. From 2014 to 2016, he served as executive director of Benitec Biopharma Inc. and helped executed the company’s US IPO. From 2012 to 2014, he was President and Chief Executive Officer of Polynoma, a Phase III cancer vaccine company, and from 2006 to 2009 he was Chief Executive Officer of Arana Therapeutics. Prior to this, Dr. Chiplin was head of the ITI Life Sciences investment fund in the UK, where he managed significant negotiations regarding funding with Government Ministers. He had been influential in various other transactions including Intrexon's acquisition of Medistem, Cephalon's acquisition of Arana Therapeutics, and GlaxoSmithKline's acquisition of Domantis. He also serves on several boards including Kings Arms Yard VCT plc and US private company Batu Biologics. Dr. Chiplin received his doctorate degree in Pharmaceutical Science from The University of Nottingham, U.K.

“We believe Dr. Chiplin’s experience in guiding multiple biotech companies through all stages of development will be invaluable to Beroni as we advance our robust pipeline through clinical development with the goal of delivering innovative therapeutics for oncology patients,” said Jacky Zhang, Chairman, and CEO of Beroni Group.

“I am honored to join the Board at a pivotal time for the Company,” said Dr. Chiplin. “Over the last several years Beroni has created an attractive pipeline of clinical programs. The Company is now entering its next phase, as it looks to accelerate its growth globally and raise the capital required for its next phase of research. I look forward to bringing my experience to the team and taking part in its journey to becoming a leading biopharmaceutical company.”

About Beroni Group Limited
Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit www.beronigroup.com.

Forward-Looking Statements Disclaimer
This press release contains forward-looking statements or forward-looking information, within the meaning of applicable United States and Australian securities laws with respect to the Company. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as “anticipate”, “will”, “expect”, “may”, “continue”, “could”, “estimate”, “forecast”, “plan”, “intend”, “believe”, “potential” and similar expressions.

Forward-looking information contained in this press release is based on Company management’s opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward-looking statements involve significant risks, uncertainties and assumptions, and there can be no assurance that such statements, or its underlying risks, uncertainties and assumptions will prove to be accurate. Factors that could cause actual results or events to differ materially include, without limitation, risks related to laws, rules and regulation applicable to the Company as well as the industry in which it operates (including in respect of taxes and other levies), economic or market conditions on both a national and global level, currency fluctuations, risks inherent to other entities at a similar stage of development and industry in which the Company currently is, competition from the Company’s competitors, unsatisfactory development or marketing of the Company and/or its products or services, regulatory action or litigation (including product liability claims), and failure to enter into agreements or arrangements with other parties on fair or reasonable terms. Forward-looking information is made only as of the date on which it is provided and, except as may be required by applicable laws, the Company disclaims any intent or obligation to update such forward-looking information whether as a result of new information, future events or otherwise.

For more information, please contact our IR consultants at:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BNIGF@dgipl.com

FAQ

What recent management changes occurred at Beroni Group?

Beroni Group appointed Dr. John Chiplin as an independent director effective April 1, 2022.

What qualifications does Dr. John Chiplin bring to Beroni Group?

Dr. Chiplin has extensive biotech experience, having led companies such as Polynoma and Benitec Biopharma.

How might Dr. Chiplin's appointment impact Beroni Group's business strategy?

His leadership is anticipated to enhance Beroni’s clinical development efforts and facilitate global growth.

What is the significance of Beroni's new direction under Dr. Chiplin?

The appointment comes as Beroni aims to accelerate its growth and raise capital for research in oncology and cell therapies.